NTGN - Big Mention In The Industry

Neon Therapeutics, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.

SHORT INTEREST
690.25K 08/15/19

P/E Current
-0.46

P/E Ratio (with extraordinary items)
-0.8

Average Recommendation: BUY

Average Target Price: 17.78